拉莫三嗪可减轻阿尔茨海默病小鼠模型的认知缺陷、突触和神经细胞损伤及标志性神经病理

Lamotrigine protects against cognitive deficits, synapse and nerve cell damage, and hallmark neuropathologies in a mouse model of Alzheimer’s disease

ES评分 0

DOI 10.4103/1673-5374.343888
刊名
年,卷(期) 2023, 18(1)
作者
作者单位 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University;
2Department of Neurology, Nanjing First Hospital, Nanjing Medical University;
Department of Pathology, Nanjing Brain Hospital, Nanjing Medical University;

摘要
拉莫三嗪(LTG)是一种广泛用于治疗癫痫的药物。新兴的临床证据表明,LTG可能改善阿尔茨海默病患者的认知功能。然而,其潜在的分子机制仍不清楚。在本研究中,使用淀粉样前体蛋白/早老素1(APP/PS1)双转基因小鼠作为阿尔茨海默病模型。对5个月大的APP/PS1小鼠每天灌胃给予一次30 mg/kg的LTG或溶剂,连续3个月。使用Morris水迷宫评估动物的认知功能。通过蛋白质印迹法(western blot)检测过度磷酸化的tau蛋白以及突触和胶质细胞标志物。使用苏木精-伊红(HE)染色研究大脑中的细胞损伤。使用酶联免疫吸附测定(ELISA)检测大脑中淀粉样蛋白-β(Aβ)的水平以及白细胞介素-1β、白细胞介素-6和肿瘤坏死因子-α的浓度。通过高通量RNA测序和实时聚合酶链反应(PCR)分析LTG治疗后大脑中的差异表达基因。我们发现,LTG显著改善了APP/PS1小鼠的空间认知缺陷;减轻了大脑中突触和神经细胞的损伤;并降低了淀粉样蛋白-β水平、tau蛋白过度磷酸化和炎症反应。高通量RNA测序揭示,LTG对阿尔茨海默病相关神经病理的有益作用可能是通过调节大脑中Ptgds、Cd74、Map3k1、Fosb和Spp1的表达介导的。这些发现揭示了LTG治疗改善阿尔茨海默病的潜在分子机制。此外,这些数据表明LTG可能是治疗阿尔茨海默病的一种有前景的治疗药物。
Abstract
Lamotrigine (LTG) is a widely used drug for the treatment of epilepsy. Emerging clinical evidence suggests that LTG may improve cognitive function in patients with Alzheimer’s disease. However, the underlying molecular mechanisms remain unclear. In this study, amyloid precursor protein/presenilin 1 (APP/PS1) double transgenic mice were used as a model of Alzheimer’s disease. Five-month-old APP/PS1 mice were intragastrically administered 30 mg/kg LTG or vehicle once per day for 3 successive months. The cognitive functions of animals were assessed using Morris water maze. Hyperphosphorylated tau and markers of synapse and glial cells were detected by western blot assay. The cell damage in the brain was investigated using hematoxylin and eosin staining. The levels of amyloid-β and the concentrations of interleukin-1β, interleukin-6 and tumor necrosis factor-α in the brain were measured using enzyme-linked immunosorbent assay. Differentially expressed genes in the brain after LTG treatment were analyzed by high-throughput RNA sequencing and real-time polymerase chain reaction. We found that LTG substantially improved spatial cognitive deficits of APP/PS1 mice; alleviated damage to synapses and nerve cells in the brain; and reduced amyloid-β levels, tau protein hyperphosphorylation, and inflammatory responses. High-throughput RNA sequencing revealed that the beneficial effects of LTG on Alzheimer’s disease-related neuropathologies may have been mediated by the regulation of Ptgds, Cd74, Map3k1, Fosb, and Spp1 expression in the brain. These findings revealed potential molecular mechanisms by which LTG treatment improved Alzheimer’s disease. Furthermore, these data indicate that LTG may be a promising therapeutic drug for Alzheimer’s disease.
关键词
阿尔茨海默病;阿尔茨海默病相关神经病理;淀粉样蛋白-β病理;APP/PS1小鼠;认知缺陷;突触和神经细胞损伤;高通量RNA测序;拉莫三嗪;神经炎症;tau蛋白过度磷酸化
KeyWord
Alzheimer’s disease; Alzheimer’s disease-related neuropathologies; amyloid-β pathology; APP/PS1 mice; cognitive deficits; damage of synapses and nerve cells; high-throughput RNA sequencing; lamotrigine; neuroinflammation; tau protein hyperphosphorylation
基金项目
页码 189-193
  • 参考文献
  • 相关文献
  • 引用本文

XinXinFu,RuiDuan,SiYuWang,QiaoQuanZhang,BinWei,TingHuang,PengYuGong,YanE,TengJiang,YingDongZhang. 拉莫三嗪可减轻阿尔茨海默病小鼠模型的认知缺陷、突触和神经细胞损伤及标志性神经病理 [J]. Neural Regeneration Research. 2023; 18; (1). 189 - 193.

  • 文献评论

相关学者

相关机构